Global Information
회사소개 | 문의 | 위시리스트

간성뇌증(HE) : 역학 예측

Hepatic Encephalopathy - Epidemiology Forecast - 2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 09월 상품 코드 534881
페이지 정보 영문 80 Pages
가격
US $ 3,250 ₩ 3,922,000 PDF by E-mail (Single User License)
US $ 6,500 ₩ 7,845,000 PDF by E-mail (Site License)
US $ 9,750 ₩ 11,768,000 PDF by E-mail (Global License)


간성뇌증(HE) : 역학 예측 Hepatic Encephalopathy - Epidemiology Forecast - 2028
발행일 : 2019년 09월 페이지 정보 : 영문 80 Pages

주요 7개국(미국, 영국, 프랑스, 이탈리아, 스페인, 일본)의 간성뇌증(HE : Hepatic Encephalopathy) 역학에 대해 조사했으며, 질환 및 시장 개요, 국가별·성별·연령·종류별 유병 수의 추이와 예측을 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 간성뇌증(HE) 시장 : 개요

  • 시장 점유율과 간성뇌증(HE)의 분포 상황(실적)
  • 시장 점유율과 간성뇌증(HE)의 분포 상황(예측)

제3장 간성뇌증(HE) : 질환 배경과 개요

  • 서론
  • 분류
  • 증상
  • 위험인자
  • 병태생리
  • 병인
  • 진단
  • 감별 진단
  • 간성뇌증 2018년 : 이탈리아 간연구협회(AISF)에 의한 임상 진료 가이드라인

제4장 역학과 환자 인구

  • 주요 조사 결과
  • 조사 방법
  • 주요 7개국의 총 유병 수
  • 주요 7개국의 총 진단 유병 수

제5장 간성뇌증(HE) 역학 : 국가별

  • 미국 역학
    • 가정과 근거
    • 총 유병 수
    • 총 진단 유병 수
    • 유병 수 : 성별
    • 유병 수 : 연령별
    • 유병 수 : 종류별
  • 유럽 5개국 역학
    • 독일
      • 총 유병 수
      • 총 진단 유병 수
      • 유병 수 : 성별
      • 유병 수 : 연령별
      • 유병 수 : 종류별
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국

제6장 일본 역학

  • 가정과 근거
  • 총 유병 수
  • 총 진단 유병 수
  • 유병 수 : 성별
  • 유병 수 : 연령별
  • 유병 수 : 종류별

제7장 부록

  • 조사 방법

제8장 DelveInsight의 서비스 내용

제9장 면책사항

제10장 DelveInsight 소개

KSA 19.09.09

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1 Clinical Description of Hepatic Encephalopathy (Adapted from AASLD-EASL Guideline 2014
  • Table 2 West Haven Criteria for hepatic encephalopathy and symptoms
  • Table 3 Stages of Hepatic Encephalopathy (HE)
  • Table 4 Total Prevalent Patient Population of Hepatic Encephalopathy in 7MM (2017-2028)
  • Table 5 Total Diagnosed Prevalent Patient Population of Hepatic Encephalopathy in 7MM (2017-2028)
  • Table 6 Total Prevalent Population of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 7 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 8 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 9 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 10 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 11 Total Prevalent Population of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 12 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 13 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 14 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 15 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 16 Total Prevalent Population of Hepatic Encephalopathy in France (2017-2028)
  • Table 17 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in France (2017-2028)
  • Table 18 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Table 19 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Table 20 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Table 21 Total Prevalent Population of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 22 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 23 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 24 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 25 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 26 Total Prevalent Population of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 27 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 28 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 29 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 30 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 31 Total Prevalent Population of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 32 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 33 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 34 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 35 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 36 Total Prevalent Population of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 37 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 38 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 39 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 40 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)

List of Figures

  • Figure 1 Symptoms of Hepatic Encephalopathy
  • Figure 2 Grading of the symptoms of Hepatic Encephalopathy
  • Figure 3 Symptoms of Hepatic Encephalopathy
  • Figure 4 Pathophysiology of hepatic encephalopathy
  • Figure 5 Pathophysiology of hepatic encephalopathy
  • Figure 6 Ammonia trafficking in hepatic encephalopathy (HE) from an organism (left panel) and an organ (right panel) perspective
  • Figure 7 The classification of HE, adapted from Amodio et al.
  • Figure 8 Total Prevalent Cases of Hepatic Encephalopathy in the 7MM (2017-2028)
  • Figure 9 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM (2017-2028)
  • Figure 10 Total Prevalent Cases of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 11 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 12 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 13 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 14 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 15 Total Prevalent Cases of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 16 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 17 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 18 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 19 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 20 Total Prevalent Cases of Hepatic Encephalopathy in France (2017-2028)
  • Figure 21 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in France (2017-2028)
  • Figure 22 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Figure 23 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Figure 24 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Figure 25 Total Prevalent Cases of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 26 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 27 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 28 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 29 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 30 Total Prevalent Cases of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 31 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 32 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 33 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 34 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 35 Total Prevalent Cases of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 36 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 37 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 38 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 39 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 40 Total Prevalent Cases of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 41 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 42 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 43 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 44 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)

DelveInsight's 'Hepatic Encephalopathy- Epidemiology Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology trends of Hepatic Encephalopathy in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Hepatic Encephalopathy - Disease Understanding

The DelveInsight Hepatic Encephalopathy report gives a thorough understanding of the Hepatic Encephalopathy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

As per the National Organization of Rare Disorders, Hepatic encephalopathy is a brain disorder that develops in some individuals with liver disease. It is a complex disorder that encompasses a spectrum or continuum of disease that ranges from a subtle condition with no outward signs or symptoms to a severe form that can cause serious, life-threatening complications. It is manifested by the broad spectrum of neuropsychiatric disturbances such as defects in cognitive, emotional, behavioral, psychomotor, and locomotive functions. This condition is characterized by personality changes, intellectual impairment, and a depressed level of consciousness.

The severity of HE is judged according to symptoms. The most commonly used staging scale of Hepatic Encephalopathy is called the West Haven Grading System. The clinically apparent forms of HE are generally described as overt HE. Overt HE can be further classified into grade II, III or IV HE based on the clinical features as originally outlined in the West Haven criteria. As mentioned above, grade I is difficult to generalize across sites, since it requires a knowledge of the patients. . In the mild stage of HE, called minimal HE (MHE) or covert HE (CHE), a person's ability to carry out daily tasks (working, driving, and sleeping) is affected and as a result, leads to poor quality of life.

Hepatic Encephalopathy - Epidemiology

The Hepatic Encephalopathy epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Hepatic Encephalopathy in 7MM, Total Diagnosed Prevalence of Hepatic Encephalopathy in 7MM, Gender-specific Diagnosed Prevalence of Hepatic Encephalopathy, Age-specific Diagnosed Prevalence of Hepatic Encephalopathy, and Type Specific Diagnosed Prevalence of Hepatic Encephalopathy) scenario of Hepatic Encephalopathy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

DelveInsight's estimations suggests that the majority of cases of Hepatic Encephalopathy are males as compared to female. There was a total of around 217,320 male and approximately 81,600 female diagnosed cases of Hepatic Encephalopathy in 2017 in the United States.

The total prevalent cases of Hepatic Encephalopathy (HE) in the 7MM was found to be approximately 525,900 in 2017, which will increase up to XXX in 2028.

Among 7MM, United States has the highest prevalent population of hepatic encephalopathy with about 298,950 cases in 2017. In 2017 among EU-5 countries, Germany has the highest number of prevalent cases with approximately 28,150, followed by France with approximately 22,800 cases and the United Kingdom with about 22,450 cases. While, Spain has the least number of prevalent cases with approximately 15,830.

In 2017, the prevalent population of Hepatic encephalopathy in Japan was found to be approximately 116,890.

Hepatic Encephalopathy (HE) is part of a spectrum of neurocognitive changes in cirrhosis. HE is divided into two broad categories based on severity, Covert Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). CHE has a significant impact on a patient's quality of life, driving performances, and has recently been associated with increased hospitalizations and death. Likewise, OHE is associated with increased rates of hospitalizations and mortality, and poor quality of life. There were total approximately 126,250 CHE and around 84,180 OHE cases of Hepatic Encephalopathy in 2017 in the United States.

Hepatic Encephalopathy Report Insights

  • The report covers a descriptive overview of the Hepatic Encephalopathy, explaining its causes, risk factors, pathophysiology and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Hepatic Encephalopathy in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in the 7MM countries with respect to the patient population.

Hepatic Encephalopathy Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Total Patient Pool with Hepatic Encephalopathy
  • Diagnosed Patient Pool of Hepatic Encephalopathy
  • Gender Specific Diagnosed Patient Pool of Hepatic Encephalopathy
  • Age Specific Diagnosed Patient Pool of Hepatic Encephalopathy
  • Type Specific Diagnosed Patient Pool of Hepatic Encephalopathy

Hepatic Encephalopathy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles

Key Benefits

  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by Severity

Table of Contents

1. Key Insights

2. Hepatic Encephalopathy Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Hepatic Encephalopathy (HE) in 2017
  • 2.2. Market Share (%) Distribution of Hepatic Encephalopathy (HE) in 2028

3. Hepatic Encephalopathy (HE): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Classification of Hepatic Encephalopathy
  • 3.3. Symptoms of Hepatic Encephalopathy
  • 3.4. Cause and risk factors of Hepatic Encephalopathy
  • 3.5. Pathophysiology
  • 3.6. Pathogenesis of Hepatic Encephalopathy
  • 3.7. Diagnosis
  • 3.8. The differential diagnosis for Hepatic Encephalopathy
  • 3.9. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Methodology
  • 4.3. 7MM Total Prevalent Patient Population of Hepatic Encephalopathy
  • 4.4. 7MM Total Diagnosed Prevalent Patient Population of Hepatic Encephalopathy

5. Country Wise-Epidemiology of Hepatic Encephalopathy

  • 5.1. United States Epidemiology
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Prevalent Cases of Hepatic Encephalopathy in the United States
    • 5.1.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States
    • 5.1.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
    • 5.1.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
    • 5.1.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
  • 5.2. EU5 Epidemiology
    • 5.2.1. Germany
      • 5.2.1.1. Assumptions and Rationale
      • 5.2.1.2. Total Prevalent Cases of Hepatic Encephalopathy in Germany
      • 5.2.1.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Germany
      • 5.2.1.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
      • 5.2.1.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
      • 5.2.1.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
    • 5.2.2. France
      • 5.2.2.1. Assumptions and Rationale
      • 5.2.2.2. Total Prevalent Cases of Hepatic Encephalopathy in France
      • 5.2.2.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in France
      • 5.2.2.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
      • 5.2.2.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
      • 5.2.2.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
    • 5.2.3. Italy
      • 5.2.3.1. Assumptions and Rationale
      • 5.2.3.2. Total Prevalent Cases of Hepatic Encephalopathy in Italy
      • 5.2.3.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Italy
      • 5.2.3.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
      • 5.2.3.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
      • 5.2.3.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
    • 5.2.4. Spain
      • 5.2.4.1. Assumptions and Rationale
      • 5.2.4.2. Total Prevalent Cases of Hepatic Encephalopathy in Spain
      • 5.2.4.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Spain
      • 5.2.4.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
      • 5.2.4.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
      • 5.2.4.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
    • 5.2.5. United Kingdom
      • 5.2.5.1. Assumptions and Rationale
      • 5.2.5.2. Total Prevalent Cases of Hepatic Encephalopathy in the United Kingdom
      • 5.2.5.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United Kingdom
      • 5.2.5.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK
      • 5.2.5.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK
      • 5.2.5.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK

6. Japan Epidemiology

  • 6.1. Assumptions and Rationale
  • 6.2. Total Prevalent Cases of Hepatic Encephalopathy in Japan
  • 6.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan
  • 6.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan
  • 6.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan
  • 6.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan

7. Appendix

  • 7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

Back to Top
전화 문의
F A Q